Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK, USA.
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK, USA.
Vet Anaesth Analg. 2020 Mar;47(2):259-266. doi: 10.1016/j.vaa.2019.11.003. Epub 2019 Dec 4.
To evaluate the analgesic effects of orally administered gabapentin on horses with chronic thoracic limb lameness.
Randomized, crossover design.
A total of 14 adult horses with chronic thoracic limb lameness.
Following baseline measurement of lameness, horses were administered each of four treatments orally in grain: treatment G, gabapentin (20 mg kg) twice daily for 13 doses; treatment F, firocoxib (171 mg once, then 57 mg once daily for six doses); treatment GF, gabapentin and firocoxib at previously stated doses and frequencies; or treatment C, grain only as a control. Treatments were administered in a randomized, crossover design, separated by 2 weeks. Subjective lameness score (SLS), inertial sensor vector sum (VS) calculations, peak vertical ground reaction force (PVGRF) measurements and vertical impulse (VI) calculations were determined immediately prior to each initial treatment dose and 2-4 hours after the final treatment dose for each treatment. Mean change in SLS, VS, PVGRF and VI for each treatment were compared among treatments.
The rank change in SLS of treatment GF was significantly greater than that of treatments C (p = 0.01) and G (p = 0.01) but not of treatment F (p = 0.08). No differences in VS (p = 0.4), PVGRF (p = 0.4) or VI (p = 0.1) were observed among treatments.
Gabapentin, as administered here, did not improve subjective or objective measures of lameness in horses with chronic thoracic limb musculoskeletal pain. Although subjective evaluation identified an improvement in lameness with treatment GF, it was not different from that observed with treatment F. Higher oral dosing and longer treatment regimens of gabapentin may be indicated for the treatment of chronic musculoskeletal pain in horses.
评估口服加巴喷丁对慢性胸肢跛行马的镇痛效果。
随机交叉设计。
共 14 匹患有慢性胸肢跛行的成年马。
在跛行的基线测量后，马以谷物的形式口服给予以下四种治疗方法中的每一种：治疗 G，加巴喷丁（20 mg/kg），每日两次，共 13 剂；治疗 F，非甾体抗炎药（171 mg 一次，然后每日 57 mg 一次，共 6 剂）；治疗 GF，按先前规定的剂量和频率给予加巴喷丁和非甾体抗炎药；或治疗 C，仅谷物作为对照。治疗以随机交叉设计进行，间隔 2 周。在每次初始治疗剂量前和每次治疗的最后一次治疗剂量后 2-4 小时，确定主观跛行评分（SLS）、惯性传感器向量和（VS）计算、峰值垂直地面反作用力（PVGRF）测量和垂直脉冲（VI）计算。比较每种治疗方法的 SLS、VS、PVGRF 和 VI 的平均变化。
治疗 GF 的 SLS 等级变化明显大于治疗 C（p=0.01）和 G（p=0.01），但不大于治疗 F（p=0.08）。VS（p=0.4）、PVGRF（p=0.4）和 VI（p=0.1）在治疗之间无差异。
此处给予的加巴喷丁并未改善患有慢性胸肢肌肉骨骼疼痛的马的主观和客观跛行测量值。尽管治疗 GF 的主观评估显示跛行有所改善，但与治疗 F 观察到的改善无差异。对于治疗马的慢性肌肉骨骼疼痛，可能需要更高的口服剂量和更长的加巴喷丁治疗方案。
